Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study

Thomas D. Schiano, Michael Charlton, Zobair Younossi, Eithan Galun, Timothy Pruett, Ran Tur-Kaspa, Rachel Eren, Shloma Dagan, Neil Graham, Paulette V. Williams, John Andrews

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

A randomized, double-blind, dose-escalation study evaluated the safety and efficacy of hepatitis C virus (HCV)-AbXTL68, a neutralizing, high-affinity, fully human, anti-E2 monoclonal antibody, in 24 HCV-positive patients undergoing liver transplantation. HCV-AbXTL68 or placebo was administered at doses from 20-240 mg as 2-4 infusions during the first 24 hours after transplantation, followed by daily infusions for 6 days, weekly infusions for 3 weeks, and either 2 or 4 weekly infusions for 8 weeks. Serum concentrations of total anti-E2 obtained during daily infusions of 120-240 mg HCV-AbXTL68 were 50-200 μg/mL above concentrations in the placebo group. Median serum concentration of HCV RNA dropped below baseline in all groups immediately after transplantation. On day 2, median change from baseline in HCV RNA was - 1.8 and -2.4 log in the 120-mg and 240-mg groups, respectively, compared with -1.5 log with placebo. The difference was lost after day 7 when the dosing frequency was reduced. The coincidence of increases in anti-E2 with decreases in HCV RNA concentration indicate that the dose-related changes in HCV RNA concentration were a result of HCV-AbXTL68 administration in the 120- and 240-mg groups. The overall incidence of nonfatal serious adverse events was higher with placebo (60%) vs. all active treatments combined (42%). In conclusion, HCV-AbXTL68 may decrease serum concentrations of HCV RNA in patients after liver transplantation. Studies evalualing more frequent daily dosing at doses > 120 mg are necessary to investigate sustained viral suppression in this populatition.

Original languageEnglish (US)
Pages (from-to)1381-1389
Number of pages9
JournalLiver Transplantation
Volume12
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Hepacivirus
Liver Transplantation
Monoclonal Antibodies
RNA
Placebos
Transplantation
Serum
Safety
Incidence

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Schiano, T. D., Charlton, M., Younossi, Z., Galun, E., Pruett, T., Tur-Kaspa, R., ... Andrews, J. (2006). Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study. Liver Transplantation, 12(9), 1381-1389. https://doi.org/10.1002/lt.20876

Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV : Results of a phase 2 randomized study. / Schiano, Thomas D.; Charlton, Michael; Younossi, Zobair; Galun, Eithan; Pruett, Timothy; Tur-Kaspa, Ran; Eren, Rachel; Dagan, Shloma; Graham, Neil; Williams, Paulette V.; Andrews, John.

In: Liver Transplantation, Vol. 12, No. 9, 09.2006, p. 1381-1389.

Research output: Contribution to journalArticle

Schiano, TD, Charlton, M, Younossi, Z, Galun, E, Pruett, T, Tur-Kaspa, R, Eren, R, Dagan, S, Graham, N, Williams, PV & Andrews, J 2006, 'Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study', Liver Transplantation, vol. 12, no. 9, pp. 1381-1389. https://doi.org/10.1002/lt.20876
Schiano, Thomas D. ; Charlton, Michael ; Younossi, Zobair ; Galun, Eithan ; Pruett, Timothy ; Tur-Kaspa, Ran ; Eren, Rachel ; Dagan, Shloma ; Graham, Neil ; Williams, Paulette V. ; Andrews, John. / Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV : Results of a phase 2 randomized study. In: Liver Transplantation. 2006 ; Vol. 12, No. 9. pp. 1381-1389.
@article{551e96cd349e4fad90c6d9e3ea5f5b2d,
title = "Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study",
abstract = "A randomized, double-blind, dose-escalation study evaluated the safety and efficacy of hepatitis C virus (HCV)-AbXTL68, a neutralizing, high-affinity, fully human, anti-E2 monoclonal antibody, in 24 HCV-positive patients undergoing liver transplantation. HCV-AbXTL68 or placebo was administered at doses from 20-240 mg as 2-4 infusions during the first 24 hours after transplantation, followed by daily infusions for 6 days, weekly infusions for 3 weeks, and either 2 or 4 weekly infusions for 8 weeks. Serum concentrations of total anti-E2 obtained during daily infusions of 120-240 mg HCV-AbXTL68 were 50-200 μg/mL above concentrations in the placebo group. Median serum concentration of HCV RNA dropped below baseline in all groups immediately after transplantation. On day 2, median change from baseline in HCV RNA was - 1.8 and -2.4 log in the 120-mg and 240-mg groups, respectively, compared with -1.5 log with placebo. The difference was lost after day 7 when the dosing frequency was reduced. The coincidence of increases in anti-E2 with decreases in HCV RNA concentration indicate that the dose-related changes in HCV RNA concentration were a result of HCV-AbXTL68 administration in the 120- and 240-mg groups. The overall incidence of nonfatal serious adverse events was higher with placebo (60{\%}) vs. all active treatments combined (42{\%}). In conclusion, HCV-AbXTL68 may decrease serum concentrations of HCV RNA in patients after liver transplantation. Studies evalualing more frequent daily dosing at doses > 120 mg are necessary to investigate sustained viral suppression in this populatition.",
author = "Schiano, {Thomas D.} and Michael Charlton and Zobair Younossi and Eithan Galun and Timothy Pruett and Ran Tur-Kaspa and Rachel Eren and Shloma Dagan and Neil Graham and Williams, {Paulette V.} and John Andrews",
year = "2006",
month = "9",
doi = "10.1002/lt.20876",
language = "English (US)",
volume = "12",
pages = "1381--1389",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV

T2 - Results of a phase 2 randomized study

AU - Schiano, Thomas D.

AU - Charlton, Michael

AU - Younossi, Zobair

AU - Galun, Eithan

AU - Pruett, Timothy

AU - Tur-Kaspa, Ran

AU - Eren, Rachel

AU - Dagan, Shloma

AU - Graham, Neil

AU - Williams, Paulette V.

AU - Andrews, John

PY - 2006/9

Y1 - 2006/9

N2 - A randomized, double-blind, dose-escalation study evaluated the safety and efficacy of hepatitis C virus (HCV)-AbXTL68, a neutralizing, high-affinity, fully human, anti-E2 monoclonal antibody, in 24 HCV-positive patients undergoing liver transplantation. HCV-AbXTL68 or placebo was administered at doses from 20-240 mg as 2-4 infusions during the first 24 hours after transplantation, followed by daily infusions for 6 days, weekly infusions for 3 weeks, and either 2 or 4 weekly infusions for 8 weeks. Serum concentrations of total anti-E2 obtained during daily infusions of 120-240 mg HCV-AbXTL68 were 50-200 μg/mL above concentrations in the placebo group. Median serum concentration of HCV RNA dropped below baseline in all groups immediately after transplantation. On day 2, median change from baseline in HCV RNA was - 1.8 and -2.4 log in the 120-mg and 240-mg groups, respectively, compared with -1.5 log with placebo. The difference was lost after day 7 when the dosing frequency was reduced. The coincidence of increases in anti-E2 with decreases in HCV RNA concentration indicate that the dose-related changes in HCV RNA concentration were a result of HCV-AbXTL68 administration in the 120- and 240-mg groups. The overall incidence of nonfatal serious adverse events was higher with placebo (60%) vs. all active treatments combined (42%). In conclusion, HCV-AbXTL68 may decrease serum concentrations of HCV RNA in patients after liver transplantation. Studies evalualing more frequent daily dosing at doses > 120 mg are necessary to investigate sustained viral suppression in this populatition.

AB - A randomized, double-blind, dose-escalation study evaluated the safety and efficacy of hepatitis C virus (HCV)-AbXTL68, a neutralizing, high-affinity, fully human, anti-E2 monoclonal antibody, in 24 HCV-positive patients undergoing liver transplantation. HCV-AbXTL68 or placebo was administered at doses from 20-240 mg as 2-4 infusions during the first 24 hours after transplantation, followed by daily infusions for 6 days, weekly infusions for 3 weeks, and either 2 or 4 weekly infusions for 8 weeks. Serum concentrations of total anti-E2 obtained during daily infusions of 120-240 mg HCV-AbXTL68 were 50-200 μg/mL above concentrations in the placebo group. Median serum concentration of HCV RNA dropped below baseline in all groups immediately after transplantation. On day 2, median change from baseline in HCV RNA was - 1.8 and -2.4 log in the 120-mg and 240-mg groups, respectively, compared with -1.5 log with placebo. The difference was lost after day 7 when the dosing frequency was reduced. The coincidence of increases in anti-E2 with decreases in HCV RNA concentration indicate that the dose-related changes in HCV RNA concentration were a result of HCV-AbXTL68 administration in the 120- and 240-mg groups. The overall incidence of nonfatal serious adverse events was higher with placebo (60%) vs. all active treatments combined (42%). In conclusion, HCV-AbXTL68 may decrease serum concentrations of HCV RNA in patients after liver transplantation. Studies evalualing more frequent daily dosing at doses > 120 mg are necessary to investigate sustained viral suppression in this populatition.

UR - http://www.scopus.com/inward/record.url?scp=33748778214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748778214&partnerID=8YFLogxK

U2 - 10.1002/lt.20876

DO - 10.1002/lt.20876

M3 - Article

C2 - 16933235

AN - SCOPUS:33748778214

VL - 12

SP - 1381

EP - 1389

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 9

ER -